TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06389370

Intervention type: OTHER
Intervention: HU-DBI questionnaire
Description: a questionnaire published by Hiroshima University (HU-DBI) to measure the Knowledge, Attitude and Behaviour of dental students through different levels of their academic years.

Intervention type: OTHER
Intervention: HU-DBI questionnaire
Description: a questionnaire published by Hiroshima University (HU-DBI) to measure the Knowledge, Attitude and Behaviour of dental students through different levels of their academic years.

Intervention type: OTHER
Intervention: HU-DBI questionnaire
Description: a questionnaire published by Hiroshima University (HU-DBI) to measure the Knowledge, Attitude and Behaviour of dental students through different levels of their academic years.

Intervention type: OTHER
Intervention: HU-DBI questionnaire
Description: a questionnaire published by Hiroshima University (HU-DBI) to measure the Knowledge, Attitude and Behaviour of dental students through different levels of their academic years.

Intervention type: OTHER
Intervention: HU-DBI questionnaire
Description: a questionnaire published by Hiroshima University (HU-DBI) to measure the Knowledge, Attitude and Behaviour of dental students through different levels of their academic years.
Study: NCT05998343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intergenerational HOW R U?
Description: 1-on-1 discussion over telephone with a trained volunteer aged 19-39 years old who has received training to provide strength-based support sessions weekly for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Same-Generation Peer Support HOW R U?
Description: 1-on-1 discussion over telephone with a trained volunteer aged 60 years or older who has received training to provide strength-based support sessions weekly for 12 weeks.
Study: NCT05359835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium DTPA and Zinc DTPA
Description: Intravenous administration of 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by 900 mL of normal saline infusion over about 90 minutes, followed by 2.5 mL (500 mg) of Ca-DTPA over one minute, followed by infusion of the remaining 100 mL of normal saline over about 10 minutes. Procedure repeated with Zn-DTPA the following day. Two-day procedure repeated at an interval of one week or more for a total of six 2-day treatment sessions.
Study: NCT06098495

Intervention type: GENETIC
Intervention: search for epigenetic profile of infertility
Description: examine the epigenetic profile of DNA extracted from MGCs and blood sample

Intervention type: GENETIC
Intervention: search for epigenetic profile of infertility
Description: examine the epigenetic profile of DNA extracted from MGCs and blood sample

Intervention type: GENETIC
Intervention: search for epigenetic profile of infertility
Description: examine the epigenetic profile of DNA extracted from MGCs and blood sample
Study: NCT05063201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 MG
Description: Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
Study: NCT05156983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-330
Description: Participants will receive TAK-330, 25 IU/kg single intravenous infusion on Day 1 and an additional dose of 25 IU/kg TAK-330 can be administered if required.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC 4F-PCC
Description: Participants will receive 4F-PCC as SOC on Day 1. The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding total dose of 50 IU/kg or 5,000 IU, whichever is smaller can be given during the surgery if required.
Study: NCT06657534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Push-pull technique
Description: push-pull technique as described by McBride et al, J Infus Nurs 2018

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOC (Standard of care)
Description: Standard of care method to obtain blood with waste blood
Study: NCT06161974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib + TMZ
Description: Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib + TMZ
Description: Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib + TMZ
Description: Olutasidenib 150 mg PO BID + Temozolomide 200 mg/m2 PO QD
Study: NCT06580197

Intervention type: OTHER
Intervention: Auricular Acupoint Therapy
Description: Ear point diagnosis and treatment is one of acupuncture and moxibustion methods, which originates from the theory of acupuncture and moxibustion meridians and is the product of the combination of modern Chinese medicine and western medicine, including two parts: auricular acupoint diagnosis and auriculotherapy. Ear point diagnosis refers to the determination of auricle positive reaction points through vision, touch, pressure and other methods to diagnose diseases in some parts of the body on the basis of ear point theory. Ear point treatment refers to the use of certain therapeutic devices on ear points to achieve the purpose of prevention and treatment of diseases by stimulating ear points, which are often carried out simultaneously in clinical practice.
Study: NCT05878964

Intervention type: OTHER
Intervention: EQ-5D-5L questionnaire
Description: Quality of life evaluation questionnaire

Intervention type: OTHER
Intervention: EQ-5D-5L questionnaire
Description: Quality of life evaluation questionnaire

Intervention type: OTHER
Intervention: FACT-G (Functional Assessment of Cancer Therapy - General)
Description: Quality of life evaluation questionnaire

Intervention type: OTHER
Intervention: FACT-G (Functional Assessment of Cancer Therapy - General)
Description: Quality of life evaluation questionnaire

Intervention type: OTHER
Intervention: FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)
Description: Self reported evaluation of cutaneous toxicity questionnaire.

Intervention type: OTHER
Intervention: FACT-EGFRI-18 (Functional Assessment of Cancer Therapy - Epidermal Growth Factor Inhibitors 18 Item)
Description: Self reported evaluation of cutaneous toxicity questionnaire.
Study: NCT06004895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actual IPL
Description: Five light pulses along lower lid region of one eye of the participant ranging from 59 to 69 Joules (J) over an area of 2.5cm by 4.5cm for each pulse

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham IPL
Description: Simulated five light pulses along lower lid region of the other eye of the same participant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT
Description: Mask with LEDs transferring a total of about 32 J/cm\^2 of energy to facial and eyelids region with their eyes closed

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LLLT
Description: Mask with LEDs transferring a total of about 32 J/cm\^2 of energy to facial and eyelids region with their eyes closed
Study: NCT05796154

Intervention type: DEVICE
Group type: OTHER
Intervention: ear blood pressure monitor
Description: The ear blood pressure monitor is a biometric monitoring device that collects blood pressure non-invasively from the ear.
Study: NCT06537622

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation group
Description: Implementation strategies to increase uptake of the clinical practice guidelines for earlier diagnosis of cerebral palsy

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: No active implementation strategies
Study: NCT04834128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCB008
Description: administration of gamma delta T cells by IV bolus injection
Study: NCT06167694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-8080; Dalpiciclib Isethionate Tablets
Description: HRS-8080 combined with Dalpiciclib Isethionate Tablets
Study: NCT05955833

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO*-trastuzumab PET scan
Description: Patients will be administered 37 MBq 89Zr-DFO\*-trastuzumab and undergo 3 PET scans on the total body PET scanner at day 1, day 2 and day 4 post-injection (p.i.). The first 3 patients will undergo an additional PET 1-2 h p.i. for dosimetry purposes. Three scans are needed for PK modelling and day 4 p.i. is chosen because it is the same time point as in historical controls. Blood samples for (radioactive) PK analysis will be taken at 10 min, 30 min, 1 h and 2 h p.i., and at every PET scan.
Study: NCT05571488

Intervention type: OTHER
Intervention: Electronic surveys
Description: Online questionnaires will be used to collect data, at recruitment and follow-up once a year

Intervention type: OTHER
Intervention: Electronic surveys
Description: Online questionnaires will be used to collect data, at recruitment and follow-up once a year

Intervention type: OTHER
Intervention: Qualitative Interviews
Description: Remote focus groups or semi-structured interviews will be proposed to a subsample of the participants, first the year after recruitment and then every two years

Intervention type: OTHER
Intervention: Qualitative Interviews
Description: Remote focus groups or semi-structured interviews will be proposed to a subsample of the participants, first the year after recruitment and then every two years
Study: NCT06656936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PharmFIT
Description: The PharmFIT intervention involves the following components: referral notice to patient, FIT ready notification, FIT ready reminders, FIT distribution, FIT completion reminders, negative and positive results notification, patient navigation support.
Study: NCT06266533

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Ultra-processed Food Nutrition Education
Description: The participants will receive a conventional nutrition education session with slides, flyers/handouts, and a lecture with discussion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arts-based Ultra-processed Food Nutrition Education
Description: The participants will receive an arts-based nutrition education session with video, animation, music, and discussion.
Study: NCT04984902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporal therapy
Description: Extracorporal therapy
Study: NCT06657482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed school start time
Description: The intervention group will start school two hours later on Mondays (at 10.15 ± 15 min) and one hour later on Tuesdays (9.15 ± 15 min) and to ordinary school start time (8.15 ± 15 min) for the rest of the week
Study: NCT06656273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FT LCP
Description: FT LCP is a behavior change software application, used as an adjunct to the standard National Diabetes Prevention Program
Study: NCT06656780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIT
Description: Participants will undergo 2 day (8 hours each) Stress Inoculation Training . This will be done in 3 steps:~Step 1: focus on education about the human body and brain and shift to hands on skills practice to improve performance in stressful conditions and is designed to improve self-and-situational awareness and the ability to manipulate reactions and responses in the body on purpose to enhance performance~Step 2: focuses on improving mental self-awareness and gaining skills in Mental Agility and Mental Flexibility~Step 3: participants will have specific simulations and real-world opportunities to practice the skills learnt.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DCA-FF
Description: Participants will undergo 8-week Standard Firefighting Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DCA-FF
Description: Participants will undergo 8-week Standard Firefighting Training
Study: NCT06657560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9231
Description: HRS-9231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9231
Description: HRS-9231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9231
Description: HRS-9231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9231
Description: HRS-9231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9231
Description: HRS-9231
Study: NCT06657339

Intervention type: PROCEDURE
Intervention: Therapeutic endoscopy endosleeve using a gastric suturing device (OverStitch™/Endomina™)
Description: The patient will undergo therapeutic endoscopy under general anesthesia, either as outpatient or inpatient care, based on the recommendations of the investigating physician, taking into account anesthetic risks and comorbidities. Two CE-marked gastric suturing devices may be used at the discretion of the investigating center based on their practices~OverStich™ allows for tissue fixation via a gastroscope, creating a durable suture through a transabdominal fixation technique. The procedure lasts about 45 minutes and includes measures to prevent vomiting.~Endomina™ is a single-use device that captures the gastric mucosa to create successive plications, allowing for effective suturing along the greater curvature of the stomach.
Study: NCT06655883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT05750914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Broadband Light
Description: Broadband Light treatment using standard protocol
Study: NCT06664567

Intervention type: BEHAVIORAL
Intervention: Colorectal cancer screening test
Description: delivery of colorectal cancer screening test by GP

Intervention type: BEHAVIORAL
Intervention: Colorectal cancer screening test
Description: delivery of colorectal cancer screening test by GP
Study: NCT06673355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dental implant prosthesis
Description: patients will receive frameworks made of high-performance polymer filled with nano zirconia and carbon

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dental implant prosthesis
Description: patients will receive frameworks made of high-performance polymer filled with nano zirconia and carbon
Study: NCT05227352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biophilic design experience
Description: Recharge Rooms are immersive, biophilic private spaces featuring multisensory input that is inspired by nature.
Study: NCT05178901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHV02
Description: live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHV02
Description: live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHV02
Description: live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHV02
Description: live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHV02
Description: live, recombinant virus consisting of vesicular stomatitis virus (VSV; Indiana) with the gene for the Zaire ebolavirus glycoprotein (GP) (EBOV GP) replacing the gene for the VSV GP; in addition, the Nipah virus (NiV) G protein is also inserted and expressed. The vaccine is administered as a single intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactated Ringer's Solution. The placebo will be administered as a single intramuscular injection
Study: NCT06656988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CO2
Description: CO2 will be used as contrast medium sparing strategy during peripheral angiography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodinated Contrast Media (ICM)
Description: Iodinated contrast medium will be used as in routine care during peripheral angiography
Study: NCT04109079

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary lymph node dissection
Description: Participants will undergo removal of at least level I and II axillary lymph nodes.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Axillary radiotherapy
Description: Axillary radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Breast or chest wall radiotherapy
Description: Breast or chest wall radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Breast or chest wall radiotherapy
Description: Breast or chest wall radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
Study: NCT06046560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor, GLP-1 RA
Description: Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor, GLP-1 RA
Description: Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education-First
Description: For the first 2-months of their participation, patients in this arm will receive curated patient education, an alert to providers, provider education, and then after 2 months, be invited to participate in the remote clinic. The patient education would consist of curated video content and informational worksheets provided by email or secure patient messaging. Provider alerts would happen through notifying of a patient's eligibility for therapy.
Study: NCT04884087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day
Description: Participants receive 3 EMA survey prompts daily for the duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA; Metricwire) Prompts 3x/day
Description: Participants receive 3 EMA survey prompts daily for the duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA; Metricwire) Prompts 6x/day
Description: Participants receive 6 EMA survey prompts daily for the duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA; Metricwire) Prompts 6x/day
Description: Participants receive 6 EMA survey prompts daily for the duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive Structure - fixed
Description: Those assigned to the fixed incentive condition will earn a fixed bonus based on EMA completion (50-74%=$3; 75-89%=$5; ≥90%=$10) each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive Structure - fixed
Description: Those assigned to the fixed incentive condition will earn a fixed bonus based on EMA completion (50-74%=$3; 75-89%=$5; ≥90%=$10) each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive Structure - prize based
Description: Those assigned to the prize-based incentive will be rewarded for high survey completion with increasing numbers of draws depending on their level of response to EMA prompts each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws). For each draw, individuals will use the EMA app to spin the wheel to see which prize amount they earn. Out of a total of 500 total draws, 50% will be $1, 43.6% will be $3, 6% will be medium prizes ($5), and 0.4% will be a jumbo prize ($90).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive Structure - prize based
Description: Those assigned to the prize-based incentive will be rewarded for high survey completion with increasing numbers of draws depending on their level of response to EMA prompts each week (50-74%=1 draw, 75-89%=2 draws, ≥90%=3 draws). For each draw, individuals will use the EMA app to spin the wheel to see which prize amount they earn. Out of a total of 500 total draws, 50% will be $1, 43.6% will be $3, 6% will be medium prizes ($5), and 0.4% will be a jumbo prize ($90).